Abstract:
A PAS-flagellin recombinant fusion protein is provided to improve toll-like receptor-5(TLR5) stimulating activity by inhibiting polymerization of flagellin molecules, thereby enhancing the unique flagellin activity. A plasmid for producing a PAS-flagellin recombinant fusion protein includes a PAS gene of SEQ ID : NO. 1 and a flagellin gene of SEQ ID : NO. 3 and has a linkage map depicted in Fig. 1. A PAS-flagellin recombinant fusion protein is produced by the plasmid and is described as SEQ ID : NO. 6. A vaccine adjuvant comprises the PAS-flagellin recombinant fusion protein as an effective ingredient.
Abstract translation:提供了一种PAS-鞭毛蛋白重组融合蛋白,通过抑制鞭毛蛋白分子的聚合来改善toll样受体-5(TLR5)刺激活性,从而增强了独特的鞭毛蛋白活性。 用于产生PAS-鞭毛蛋白重组融合蛋白的质粒包括SEQ ID NO:1的PAS基因。 1和SEQ ID NO:1的鞭毛蛋白基因。 并具有图3所示的连杆图。 PAS-鞭毛蛋白重组融合蛋白由质粒产生并描述为SEQ ID NO: 疫苗佐剂包含PAS-鞭毛蛋白重组融合蛋白作为有效成分。
Abstract:
본 발명은 패혈증 비브리오균( Vibrio vulnificus )의 생체 내 발현 단백질인 PyrH에 관한 것으로, 보다 상세하게는 패혈증 비브리오균의 생존 필수 인자인 PyrH(또는 Uridylate kinase) 돌연변이체를 이용한 백신 개발 및 PyrH 단백질을 이용한 항균물질 탐색과 개발에 관한 것이다. 패혈증 비브리오균, 생존 필수 인자, PyrH, 돌연변이, 백신, 항균물질
Abstract:
본 발명은 플라젤린을 포함하는 천식 및 알레르기 질환 면역 치료제에 관한 것으로서, 보다 상세하게는 플라젤린을 유효 성분으로 함유시킴으로써 천식, 아토피성 피부염, 알레르기성 비염 등과 같은 알레르기 질환에 대한 항원 특이적 면역 반응을 조절하는 면역치료제에 관한 것이다. 항원 특이적 천식 치료제, 플라젤린, 패혈증 비브리오균, 면역 치료제
Abstract:
An immuno-therapy adjuvant composition comprising flagellins is provided to be able to control antigen-specific immuno-reaction against allergic diseases such as asthma, atopic dermatitis and allergic rhinitis. The adjuvant composition for treating asthma and allergic diseases comprises flagellins of septic vibrio as an effective ingredient. In the composition, the flagellins are encoded by a gene selected from the group consisting of flaA, flaB, flaF, flaC, flaD, and flaE.
Abstract:
본 발명은 비브리오 패혈증균( Vibrio vulnificus )의 독력인자들의 발현을 조절하는 범독력인자 발현 조절인자(global virulence regulator)인 cAMP 수용체 단백질(CRP) 및 이에 결합하는 cAMP를 생합성하는 아데닐레이트 사이클라아제(adenylate cyclase) 유전자에 관한 것으로, cAMP 수용체 단백질 유전자 및 아데닐레이트 사이클라아제 유전자를 결실시킨 돌연변이 균주를 함유하는 항 비브리오 패혈증 백신, 특히 생균 백신으로 제조하는 방법에 관한 것이다.
Abstract:
PURPOSE: cAMP receptor protein and adenylate cyclase of Vibrio vulnificus as global virulence regulators to regulate virulence expression are provided. Therefore, the host cell is protected from infection of Vibrio vulnificus by deleting genes encoding the cAMP receptor protein and adenylate cyclase. CONSTITUTION: The crp gene encoding the cAMP receptor protein(CRP) of Vibrio vulnificus to regulate virulence expression has the nucleotide sequence of SEQ ID NO:1, wherein the cAMP receptor protein(CRP) of Vibrio vulnificus has the amino acid sequence of SEQ ID NO:2. The cya gene encoding the adenylate cyclase of Vibrio vulnificus which binds to the CRP to activate the CRP has the nucleotide sequence of SEQ ID NO:3, wherein the adenylate cyclase of Vibrio vulnificus has the amino acid sequence of SEQ ID NO:4.
Abstract translation:目的:提供创伤弧菌的cAMP受体蛋白和腺苷酸环化酶,作为调控毒力表达的全局毒力调节因子。 因此,通过删除编码cAMP受体蛋白质和腺苷酸环化酶的基因,保护宿主细胞免受创伤弧菌的感染。 构成:编码创伤弧菌的cAMP受体蛋白(CRP)的crp基因用于调节毒力表达具有SEQ ID NO:1的核苷酸序列,其中创伤弧菌的cAMP受体蛋白(CRP)具有SEQ ID NO:1的氨基酸序列 NO:2。 结合CRP以激活CRP的编码创伤弧菌的腺苷酸环化酶的cya基因具有SEQ ID NO:3的核苷酸序列,其中创伤弧菌的腺苷酸环化酶具有SEQ ID NO:4的氨基酸序列。
Abstract:
PURPOSE: A pharmaceutical vaccine composition for fowl typhoid and a feed composition for preventing fowl typhoid are provided to induce prepare antibiotics and to effectively prevent or treat fowl typhoid. CONSTITUTION: A pharmaceutical vaccine composition for fowl typhoid contains ppGpp(guanosine 5'-diphosphate 3'-diphosphate)-deletion mutant Salmonella Gallinarum. The strain contains inactivated relA gene, spoT gene encoding ppGpp synthase, or activated relA gene and spoT gene. A feed composition for preventing fowl typhoid contains the ppGpp-deletion mutant Salmonella Gallinarum. The composition is manufactured in the form of a tablet, pill, powder, granule, capsule, suspension, emulsion, or syrup.